227 related articles for article (PubMed ID: 20408801)
21. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
Tonge PJ; Kisker C; Slayden RA
Curr Top Med Chem; 2007; 7(5):489-98. PubMed ID: 17346194
[TBL] [Abstract][Full Text] [Related]
22. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
25. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor.
Lei B; Wei CJ; Tu SC
J Biol Chem; 2000 Jan; 275(4):2520-6. PubMed ID: 10644708
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
27. 1H and 13C NMR characterization of pyridinium-type isoniazid-NAD adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis.
Broussy S; Bernardes-Génisson V; Coppel Y; Quémard A; Bernadou J; Meunier B
Org Biomol Chem; 2005 Feb; 3(4):670-3. PubMed ID: 15703806
[TBL] [Abstract][Full Text] [Related]
28. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
[TBL] [Abstract][Full Text] [Related]
29. Fragment-Based Design of
Sabbah M; Mendes V; Vistal RG; Dias DMG; Záhorszká M; Mikušová K; Korduláková J; Coyne AG; Blundell TL; Abell C
J Med Chem; 2020 May; 63(9):4749-4761. PubMed ID: 32240584
[TBL] [Abstract][Full Text] [Related]
30. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Encinas L; O'Keefe H; Neu M; Remuiñán MJ; Patel AM; Guardia A; Davie CP; Pérez-Macías N; Yang H; Convery MA; Messer JA; Pérez-Herrán E; Centrella PA; Alvarez-Gómez D; Clark MA; Huss S; O'Donovan GK; Ortega-Muro F; McDowell W; Castañeda P; Arico-Muendel CC; Pajk S; Rullás J; Angulo-Barturen I; Alvarez-Ruíz E; Mendoza-Losana A; Ballell Pages L; Castro-Pichel J; Evindar G
J Med Chem; 2014 Feb; 57(4):1276-88. PubMed ID: 24450589
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
[TBL] [Abstract][Full Text] [Related]
32. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
[TBL] [Abstract][Full Text] [Related]
34. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
35. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
36. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
Tripathi A; Wadia N; Bindal D; Jana T
Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
[TBL] [Abstract][Full Text] [Related]
37. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
[TBL] [Abstract][Full Text] [Related]
38. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
[TBL] [Abstract][Full Text] [Related]
39. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Vilchèze C; Jacobs WR
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
